Get the Stockscreener App
43.54
0.96%
-0.42
After Hours:
43.60
0.06
+0.14%
Overview
News
Price History
Option Chain
Financials
Why BMY Down?
Discussions
Forecast
Stock Split
Dividend History
Bristol Myers Squibb Co stock is traded at $43.54, with a volume of 13.16M.
It is down -0.96% in the last 24 hours and down -5.76% over the past month.
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
See More
Previous Close:
$43.96
Open:
$43.68
24h Volume:
13.16M
Relative Volume:
0.98
Market Cap:
$88.62B
Revenue:
$47.70B
Net Income/Loss:
$5.07B
P/E Ratio:
17.57
EPS:
2.4784
Net Cash Flow:
$14.58B
1W Performance:
-3.54%
1M Performance:
-5.76%
6M Performance:
-14.14%
1Y Performance:
-16.59%
1-Day Range:
$43.29
$44.23
1-Week Range:
$43.29
$45.19
52-Week Range:
$42.96
$63.33
Bristol Myers Squibb Co Stock (BMY) Company Profile
Name
Bristol Myers Squibb Co
Sector
Industry
Phone
(609) 252-4621
Address
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Compare BMY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
43.54 | 89.48B | 47.70B | 5.07B | 14.58B | 2.4784 |
|
LLY
Lilly Eli Co
|
819.40 | 747.19B | 53.26B | 13.80B | -50.20M | 15.08 |
|
JNJ
Johnson Johnson
|
190.90 | 459.32B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
230.30 | 407.19B | 58.33B | 3.73B | 18.24B | 2.1013 |
|
NVS
Novartis Ag Adr
|
129.12 | 251.72B | 53.40B | 13.68B | 16.89B | 6.8864 |
|
MRK
Merck Co Inc
|
85.70 | 214.78B | 63.43B | 16.42B | 14.72B | 6.4861 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-05-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Apr-22-25 | Initiated | Piper Sandler | Overweight |
| Dec-16-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-13-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Nov-12-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-25-24 | Downgrade | Citigroup | Buy → Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jul-29-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-11-24 | Downgrade | Societe Generale | Buy → Hold |
| Feb-06-24 | Downgrade | Redburn Atlantic | Buy → Neutral |
| Jan-03-24 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-15-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Oct-27-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Oct-27-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Oct-27-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jul-10-23 | Initiated | SVB Securities | Market Perform |
| Jun-28-23 | Initiated | Daiwa Securities | Outperform |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Jan-17-23 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-18-22 | Initiated | Credit Suisse | Neutral |
| Oct-10-22 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-14-22 | Downgrade | Berenberg | Buy → Hold |
| Jun-03-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Underweight |
| Dec-17-21 | Initiated | Goldman | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Nov-01-21 | Downgrade | Argus | Buy → Hold |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-30-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-13-21 | Upgrade | Truist | Hold → Buy |
| Nov-16-20 | Upgrade | Societe Generale | Hold → Buy |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Nov-06-20 | Downgrade | Gabelli & Co | Buy → Hold |
| Oct-19-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Jul-28-20 | Initiated | Raymond James | Outperform |
| Apr-02-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-06-20 | Resumed | Citigroup | Buy |
| Dec-13-19 | Upgrade | Argus | Hold → Buy |
| Nov-22-19 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Aug-14-19 | Upgrade | Atlantic Equities | Neutral → Overweight |
| May-28-19 | Initiated | Goldman | Buy |
| May-20-19 | Downgrade | Argus | Buy → Hold |
| May-03-19 | Upgrade | Barclays | Equal Weight → Overweight |
| May-03-19 | Resumed | JP Morgan | Overweight |
| Jan-15-19 | Upgrade | Societe Generale | Sell → Buy |
| Oct-22-18 | Downgrade | Citigroup | Buy → Neutral |
View All
Bristol Myers Squibb Co Stock (BMY) Latest News
Why Top Investors Are Buying Bristol-Myers Squibb Co (BMY) - The Acquirer's Multiple
Pharma companies announce direct-to-consumer sales and price cuts in US - Reuters
Pancreatic Endocrine Tumor Market Set to Witness Significant Growth During the Forecast Period (2025–2034) Owing to the Expected Launch of Therapies | DelveInsight - GlobeNewswire Inc.
Trend analysis for Bristol Myers Squibb Company this weekJuly 2025 Outlook & Weekly Setup with High ROI Potential - newser.com
SystImmune to Receive Milestone Payment from Bristol Myers Squibb Under Iza-Bren Collaboration - BioSpace
Mark Cuban’s Pharmacy Targets Drug Pricing Reform as AstraZeneca Invests $4.5 Billion in Virginia and Bristol Myers Squibb Acquires Orbital Therapeutics for $1.5 Billion - geneonline.com
Stock Looks Undervalued As Bristol Myers Buys Orbital Therapeutics (NYSE:BMY) - Seeking Alpha
Bristol Myers (BMY) Triggers Milestone Payment with SystImmune C - GuruFocus
SystImmune receives $250 million milestone payment from Bristol Myers Squibb - Investing.com
Covington aids Bristol Myers Squibb on Orbital Therapeutics acquisition - ICLG.com
Notable healthcare headlines for the week: Novo Nordisk, Bristol Myers Squibb and J&J in focus - Seeking Alpha
Bristol-Myers Squibb (BMY): Exploring Valuation After Recent Share Price Declines - simplywall.st
Bristol Myers Squibb: Value Emerges From Distress - Seeking Alpha
Bristol Myers Squibb’s Alzheimer’s Drug, BMS-986446, Granted FDA Fast Track Status - Yahoo Finance
Conning Inc. Has $33.17 Million Stake in Bristol Myers Squibb Company $BMY - MarketBeat
Fourpath Capital Management LLC Trims Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
CAR Ts for autoimmune ramp up: BMS buying Orbital for $1.5B - BioWorld MedTech
BMS expands CAR-T portfolio with $1.5bn Orbital buyout - Pharmaceutical Technology
Bristol Myers to buy Cambridge startup Orbital Therapeutics, building out cell therapy pipeline - The Boston Globe
Bristol Myers buys Orbital Therapeutics for $1.5 billion in cell therapy push | Business Information & News | FE - Westlaw Today
Bristol-Myers Squibb (BMY) Expands Cell Therapy Portfolio with $1.5 Billion Acquisition - GuruFocus
Chart based analysis of Bristol Myers Squibb Company trendsEntry Point & Fast Moving Market Watchlists - newser.com
Bristol Myers Squibb buys Cambridge biotech for $1.5B - The Business Journals
BMS latest to enter in vivo CAR-T field with $1.5B Orbital buy - FirstWord Pharma
Bristol Myers buys Orbital Therapeutics for $1.5 billion in cell therapy push - Reuters
Bristol Myers Squibb To Acquire Orbital Therapeutics - citybiz
Bristol Myers makes $1.5B bid for Orbital Therapeutics - The Pharma Letter
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Bristol Myers buys Orbital Therapeutics for $1.5 billion in cell therapy push By Reuters - Investing.com
Bristol Myers (BMY) to Acquire Orbital Therapeutics in $1.5 Bill - GuruFocus
Bristol Myers Squibb (BMY) Expands with Orbital Therapeutics Acq - GuruFocus
Bristol Myers Squibb to acquire Orbital for $1.5B - NJBIZ
Bristol Myers Squibb to acquire Orbital Therapeutics for $1.5 billion - Investing.com
$1.5B deal: Bristol Myers Squibb acquires Orbital, gaining OTX-201 and RNA in vivo CAR T platform - Stock Titan
Bristol Myers Squibb and TV Host Gail Simmons Tackle Stigma in Schizophrenia with New Initiative Spotlighting the Power of Support and Connection – Company AnnouncementFT.com - Financial Times
Blair William & Co. IL Sells 222,590 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Bristol-Myers Squibb: Your Chance To Buy A Bargain 6% Yield (NYSE:BMY) - Seeking Alpha
Bristol Myers Squibb Company $BMY Shares Sold by Vontobel Holding Ltd. - MarketBeat
Why Bristol Myers Squibb (BMY) is a Top Value Stock for the Long-Term - Yahoo Finance
Abel Hall LLC Has $444,000 Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Shell Asset Management Co. Raises Position in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb Company $BMY Shares Sold by Kingswood Wealth Advisors LLC - MarketBeat
Pharmaceutical research and development pipeline - Bristol Myers Squibb
Cell Therapy Market Set for Dynamic Growth with Key Players Bristol Myers Squibb Company, Amgen Inc. - industrytoday.co.uk
Bristol Myers Squibb 2025: Rewiring the company - PharmaLive
Bristol Myers Squibb Company $BMY Shares Sold by Grimes & Company Inc. - MarketBeat
Ameriflex Group Inc. Lowers Stake in Bristol Myers Squibb Company $BMY - MarketBeat
Investing Smart: Bristol-Myers Squibb (BMY) Among the Best Affordable Dividend Stocks - Yahoo
Alta Wealth Advisors LLC Has $462,000 Stock Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb Company $BMY Shares Sold by QRG Capital Management Inc. - MarketBeat
Bristol Myers Squibb Stock Hits Day High with Strong Intraday Performance - Markets Mojo
Bristol Myers Squibb Co Stock (BMY) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.48%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):